After years of regulatory delay, isolated court decisions, and a market eager for innovative treatments, Brazil has finally enacted rules authorizing the cultivation of Cannabis sativa L. for medical, pharmaceutical, and scientific research purposes. The move by the National Health Surveillance Agency (ANVISA) is undoubtedly relevant, but it is far from representing a structural turning point. Brazil has moved forward, yet it continues to regulate as if it mistrusted its own progress.
Author:
Marianne Albers